Eleftheria A. Anastasopoulou

Author

Also Known As

E Anastasopoulou, E. A. Anastasopoulou, E. Anastasopoulou, E.A. Anastasopoulou, ELEFTHERIA A ANASTASOPOULOU, ELEFTHERIA ANASTASOPOULOU, Eleftheria A Anastasopoulou, Eleftheria A. Anastasopoulou, Eleftheria Anastasopoulou

Publications

465

Citations

H-Index

Concepts

All Affiliations

St Savas Hospital The University of Texas MD Anderson Cancer Center Brooke Army Medical Center Levine Cancer Institute University of Tübingen

About

Eleftheria A. Anastasopoulou is an author at St Savas Hospital specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	236
2	Immunology	7	7	216
3	Engineering	1	1	12
4	Health Sciences	1	1	20
5	Nursing	1	1	20

Eleftheria A. Anastasopoulou

Publications

435

Citations

H-Index

Page 1

	Year	Citations
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence Elizabeth A. Mittendorf, Alexandros Ardavanis, James T. Symanowski, Annals of Oncology VaccinationBreast OncologyBreast Cancer PatientsMedicineImmunology	2016	107
Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer Sotirios P. Fortis, Michael Sofopoulos, Nectaria N. Sotiriadou, Journal for ImmunoTherapy of Cancer	2017	93
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence Tommy A. Brown, Elizabeth A. Mittendorf, Diane F. Hale, Breast Cancer Research and Treatment	2020	75
AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial Sonia A. Perez, Eleftheria A. Anastasopoulou, Panagiotis Tzonis, Cancer Immunology Immunotherapy VaccinationAe37 Peptide VaccinationImmunologyTumor ImmunityTherapeutic Vaccine	2013	32
AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction Sonia A. Perez, Eleftheria A. Anastasopoulou, Michael Papamichail, Cancer Immunology Immunotherapy Biomarker (Medicine)Prognostic BiomarkersUrologyAe37 Peptide VaccinationGenitourinary Cancer	2014	20
Cardiac rehabilitation effects on quality of life in patients after acute myocardial infarction. H. Antonakoudis, Konstantinos Kifnidis, A Andreadis, PubMed Quality Of LifePhysical ActivityExercise RehabilitationAcute Myocardial InfarctionStroke Rehabilitation	2006	20
A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A24 and HLA-DRB111 alleles may be prognostic and predictive biomarkers for clinical benefit Eleftheria A. Anastasopoulou, Ioannis F. Voutsas, Theodora Keramitsoglou, Cancer Immunology Immunotherapy HlaHistocompatibilityOncologyMedicineProstate Cancer Patients	2015	18
MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4<sup>+</sup>T-cells Eleftheria A. Anastasopoulou, Ioannis F. Voutsas, Michael Papamichail, OncoImmunology	2016	17
Immune profiling of melanoma tumors reflecting aggressiveness in a preclinical model Sotirios P. Fortis, Louisa G. Mahaira, Eleftheria A. Anastasopoulou, Cancer Immunology Immunotherapy Melanoma TumorsImmune EvasionTumor ImmunologyCancer ImmunosurveillancePreclinical Model	2017	15
Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide Ioannis F. Voutsas, Eleftheria A. Anastasopoulou, Panagiotis Tzonis, Journal for ImmunoTherapy of Cancer	2016	14

Page 1